Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment
Author:
Affiliation:
1. CRS Clinical Research Services Kiel GmbH; Kiel; Germany
2. CRS Clinical Research Services Mannheim GmbH; Grünstadt; Germany
3. Nephrologisches Zentrum; Rendsburg; Germany
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.29/fullpdf
Reference15 articles.
1. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes;Avignon;Diabetes Care.,1997
2. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes;Nauck;Diabetologia.,1986
3. Trends in the prevalence of diabetic neuropathy in type 1 and type 2 diabetes;Harvey;Curr Opin Nephron Hypertens.,2003
4. Standards of medical care in diabetes;American Diabetes Association;Diabetes Care.,2011
5. Pharmackinetics of dipeptidylpeptidase-4 inhibitors;Scheen;Diabetes Obes Metab.,2010
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle;European Journal of Pharmacology;2022-11
2. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition;Acta Pharmaceutica Sinica B;2022-11
3. QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2);Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2021-09
4. Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans;Frontiers in Pharmacology;2021-08-26
5. A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression;International Journal of Molecular Sciences;2020-07-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3